Previous 10 | Next 10 |
Lyra Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update PR Newswire In April 2022 , secured $100.5 million in gross proceeds in an at-the-market, private placement of common stock that is expected to support two pivotal data...
Lyra Therapeutics to Present at Upcoming Investor Conferences PR Newswire WATERTOWN, Mass. , May 5, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to ena...
Lyra Therapeutics Presents Positive Data from LANTERN Phase 2 Study of LYR-210 for Treatment of Chronic Rhinosinusitis at COSM 2022 PR Newswire LYR-210 provided up to 24 weeks of clinically meaningful global symptom improvement in CRS patients LYR-210 achieved ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Insider trading is a valuable metric for investors and can hint at future performance of these seven stocks. Alphabet ( GOOG )( GOOGL ): Co-founders’ sales accelerate, and executives joined them, but the...
Lyra Therapeutics Announces First Patient Treated in Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients PR Newswire WATERTOWN, Mass. , April 25, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (NASDAQ: LYRA), a clinical...
Today, we put Lyra Therapeutics in the spotlight for the first time. This small biopharma concern has disappointed investors since coming public in mid-2020. The drop in the shares has triggered some huge insider buying by insiders and beneficial owners of the stock via a capital ...
Lyra Therapeutics Announces Two Presentations at Upcoming COSM 2022 PR Newswire LYR-210 Data on Impact of Long-Acting Implantable Corticosteroid Matrices in Patients with CRS Selected as a Top Clinical Abstract Both Presentations Demonstrate Potential Benefit o...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Another day of trading is waiting for investors and we’re kicking it off with a look at the biggest pre-market stock movers for Wednesday! Source: Eric Urquhart/Shutterstock.com We’ve got buyout rumors...
Gainers: Checkmate Pharmaceuticals (CMPI) +332%. Sono Group (SEV) +66%. ToughBuilt Industries (TBLT) +55%. Petros Pharmaceuticals (PTPI) +40%. Axsome Therapeutics (AXSM) +25%. Cyren (CYRN) +22%. Super Micro Computer (SMCI) +21%. Pulse Biosciences (PLSE) +18%. Annexon (ANNX) +18%. Olema Pharma...
Gainers: Checkmate Pharmaceuticals CMPI +333%. Petros Pharmaceuticals (PTPI) +55%. Axsome Therapeutics AXSM +23%. Avinger (AVGR) +11%. Processa Pharmaceuticals (PCSA) +10%. Losers: Lyra Therapeutics (LYRA) -16%. Diffusion Pharmaceuticals (DFFN) -15...
News, Short Squeeze, Breakout and More Instantly...
Lyra Therapeutics Inc. Company Name:
LYRA Stock Symbol:
NASDAQ Market:
Lyra Therapeutics Inc. Website:
WATERTOWN, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of patients with chronic rhinosinusitis (CRS), today announced that Maria Palasis, Ph.D., President and Chi...
WATERTOWN, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced th...
-- ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Pre-Surgical Chronic Rhinosinusitis (CRS) on Track to Complete Enrollment in mid-2023 -- -- Data from BEACON Phase 2 Trial of LYR-220 in Post-Surgical CRS Anticipated Q4 2023 -- -- Advancing In-House Manufacturing Capabilities to ...